Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu multicentrická studie, časopisecké články
PubMed
37058479
PubMed Central
PMC10112941
DOI
10.1182/bloodadvances.2022009578
PII: 495340
Knihovny.cz E-zdroje
- MeSH
- adaptorové proteiny signální transdukční MeSH
- antigeny CD19 MeSH
- COVID-19 * terapie MeSH
- imunoterapie adoptivní MeSH
- lidé MeSH
- monoklonální protilátky MeSH
- retrospektivní studie MeSH
- SARS-CoV-2 MeSH
- testování na COVID-19 MeSH
- vakcinace MeSH
- vakcíny proti COVID-19 MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- Názvy látek
- adaptorové proteiny signální transdukční MeSH
- antigeny CD19 MeSH
- monoklonální protilátky MeSH
- vakcíny proti COVID-19 MeSH
Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared with patients infected with previous variants (7% vs 58% [P = .012]). Twenty-six patients were vaccinated at the time of the COVID-19 diagnosis. Two vaccinations showed a marked but unsignificant reduction in the risk of COVID-19-caused mortality (33.3% vs 14.2% [P = .379]). In addition, the course of the disease appears milder with less frequent intensive care unit admissions (39% vs 14% [P = .054]) and a shorter duration of hospitalization (7 vs 27.5 days [P = .022]). Of the available treatment options, only monoclonal antibodies seemed to be effective at reducing mortality from 32% to 0% (P = .036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. This trial was registered at www.clinicaltrials.gov as #NCT04733729.
Aristotle University of Thessaloniki Thessaloniki Greece
Azienda Ospedaliera Nazionale SS Antonio e Biagio e Cesare Arrigo Alessandria Italy
Centre Hospitalier d'Argenteuil Argenteuil France
Centre Hospitalier de Versailles Le Chesnay France
Centro de Investigación Biomédica en Red Instituto de Salud Carlos 3 Madrid Spain
Complejo Hospitalario de Navarra Iruña Pamplona Spain
Departament de Medicina Universitat Autònoma de Barcelona Bellaterra Spain
Department of Hematology and Oncology Medical University of Innsbruck Innsbruck Austria
Department of Hematology UZ Leuven Leuven Belgium
Department of Infectious Diseases Karolinska University Hospital Stockholm Sweden
Department of Microbiology Immunology and Transplantation KU Leuven Leuven Belgium
Department of Nephrology and Infectious Diseases AZ Sint Jan Brugge Oostende AV Brugge Belgium
Department of Oncohematology Comenius University and National Cancer Institute Bratislava Slovakia
Faculty of Medicine University Medical Center Hamburg Eppendorf Hamburg Germany
Fundacion Jimenez Diaz University Hospital Health Research Institute IIS FJD Madrid Spain
German Centre for Infection Research Partner Site Bonn Cologne Cologne Germany
Hematology and Stem Cell Transplant Unit IRCCS Regina Elena National Cancer Institute Rome Italy
Hematology Department Hospital Universitario de Salamanca Salamanca Spain
Hematology Unit Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Hospital Universitario 12 de Octubre Madrid Spain
Hospital Universitario Infanta Leonor Madrid Spain
Hospital Universitario Marqués de Valdecilla Santander Spain
Hospital Univesitario Virgen del Rocío Seville Spain
IRCCS Ospedale San Raffaele Milan Italy
Istituto Oncologico della Svizzera Italiana Bellinzona Switzerland
King's College Hospital London United Kingdom
La Paz University Hospital Madrid Spain
Ospedale San Bortolo Vicenza Italy
Portuguese Institute of Oncology Lisbon Portugal
School of Medicine University of Zagreb Zagreb Croatia
Service d'Hematologie Oncologie Hopital St Louis Assistance Publique Hopitaux de Paris Paris France
Universite de Paris Diderot Paris France
University Hospital Centre Zagreb Zagreb Croatia
University Medical Center Groningen Groningen The Netherlands
University of Milan and Fondazione IRCCS Istituto Nazionale Dei Tumori Milan Italy
Zobrazit více v PubMed
Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544. PubMed PMC
Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56. PubMed
Strati P, Varma A, Adkins S, et al. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica. 2021;106(10):2667–2672. PubMed PMC
Jacobson C, Locke FL, Ghobadi A, et al. Long-term survival and gradual recovery of B cells in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel) Blood. 2020;136(suppl 1):40–42.
Busca A, Salmanton-Garcia J, Corradini P, et al. COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP. Blood Adv. 2022;6(7):2427–2433. PubMed PMC
Spanjaart AM, Ljungman P, de La Camara R, et al. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Leukemia. 2021;35(12):3585–3588. PubMed PMC
Haggenburg S, Lissenberg-Witte BI, van Binnendijk RS, et al. Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. Blood Adv. 2022;6(5):1537–1546. PubMed PMC
Dhakal B, Abedin S, Fenske T, et al. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. Blood. 2021;138(14):1278–1281. PubMed PMC
Gastinne T, Le Bourgeois A, Coste-Burel M, et al. Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy. Br J Haematol. 2022;196(2):360–362. PubMed PMC
Okamoto A, Fujigaki H, Iriyama C, et al. CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma. Blood Adv. 2022;6(11):3230–3233. PubMed PMC
Marasco V, Carniti C, Guidetti A, et al. T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies. Br J Haematol. 2022;196(3):548–558. PubMed PMC
Atanackovic D, Kreitman RJ, Cohen J, et al. T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine. J Immunother Cancer. 2022;10(7):e004953. PubMed PMC
Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23(2):186–193. PubMed
Salmanton-Garcia J, Busca A, Cornely OA, et al. EPICOVIDEHA: a ready to use platform for epidemiological studies in hematological patients with COVID-19. Hemasphere. 2021;5(7):e612. PubMed PMC
Ward IL, Bermingham C, Ayoubkhani D, et al. Risk of COVID-19 related deaths for SARS-CoV-2 Omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study. BMJ. 2022;378:e070695. PubMed PMC
Bechman K, Yates M, Mann K, et al. Inpatient COVID-19 mortality has reduced over time: results from an observational cohort. PLoS One. 2022;17(1):e0261142. PubMed PMC
Pagano L, Salmanton-Garcia J, Marchesi F, et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey. Blood. 2022;140(26):2773–2787. PubMed PMC
Salmanton-Garcia J, Marchesi F, Glenthoj A, et al. Improved clinical outcome of COVID-19 in hematologic malignancy patients receiving a fourth dose of anti-SARS-CoV-2 vaccine: an EPICOVIDEHA report. Hemasphere. 2022;6(11):e789. PubMed PMC
Haggenburg S, Hofsink Q, Lissenberg-Witte BI, et al. COBRA KAI Study Team Antibody response in immunocompromised patients with hematologic cancers who received a 3-dose mRNA-1273 vaccination schedule for COVID-19. JAMA Oncol. 2022;8(10):1477–1483. PubMed PMC
Blennow O, Salmanton-Garcia J, Nowak P, et al. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: an EPICOVIDEHA survey report. Am J Hematol. 2022;97(8):E312–E317. PubMed PMC
Bachy E, Le Gouill S, Di Blasi R, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28(10):2145–2154. PubMed PMC
Kuhnl A, Roddie C, Kirkwood AA, et al. A national service for delivering CD19 CAR-Tin large B-cell lymphoma - the UK real-world experience. Br J Haematol. 2022;198(3):492–502. PubMed
Bethge WA, Martus P, Schmitt M, et al. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood. 2022;140(4):349–358. PubMed
Bhaskaran K, Bacon S, Evans SJ, et al. Factors associated with deaths due to COVID-19 versus other causes: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet Reg Health Eur. 2021;6:100109. PubMed PMC
ClinicalTrials.gov
NCT04733729
